YH 009
Alternative Names: YH-009Latest Information Update: 08 Dec 2021
At a glance
- Originator Beijing Biocytogen
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 30 Nov 2021 YH 009 is available for licensing as of 30 Nov 2021. https://biocytogen.com/pipeline/yh009/
- 29 Nov 2021 Preclinical trials in Respiratory syncytial virus infections (Prevention) in China (Parenteral) (Eucure Biopharma pipeline, November 2021)
- 29 Nov 2021 Preclinical trials in Respiratory syncytial virus infections in China (Parenteral) (Eucure Biopharma pipeline, November 2021)